Dupixent approved in the US as the first-ever biologic medicine …
WEB4 days ago · Paris and Tarrytown, NY, September 27, 2024. The US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) as an add-on maintenance treatment of adults with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype. Dupixent is the first biologic medicine approved in the US to treat these ...
Dupixent® (dupilumab) Approved in the U.S. as the First-ever
WEB3 days ago · Dupixent is indicated for the approximately 300,000 adults in the U.S. with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype. Following recent ...
Press Release: Dupixent approved in the US as the first-ever …
WEB3 days ago · The US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) as an add-on maintenance treatment of adults with inadequately controlled chronic obstructive pulmonary disease (COPD ...
Regeneron, Sanofi's Dupixent Get FDA Approval For Chronic Obstructive ...
WEB3 days ago · Regeneron Pharmaceuticals, Inc. and Sanofi (), Friday announced that the U.S. Food and Drug Administration has approved Dupixent as an add-on maintenance treatment of adults with inadequately controlled chronic obstructive pulmonary disease or COPD and an eosinophilic phenotype.Sanofi claimed that Dupixent will be nation's first biologic medicine approved for these conditions.
Regeneron, Sanofi's Dupixent Get FDA Approval For Chronic Obstructive ...
WEB3 days ago · Sanofi claimed that Dupixent will be nation's first biologic medicine approved for these conditions. COPD is a respiratory disease that damages the lungs and causes progressive lung function decline.
Update on FDA Priority Review of Dupixent® (dupilumab) for the ...
WEBMay 31, 2024 · Recently, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion and recommended the approval of Dupixent as an add-on maintenance treatment in adults with uncontrolled COPD characterized by raised blood eosinophils.
Dupixent® late-breaking data from NOTUS confirmatory phase 3 …
WEBMay 20, 2024 · NOTUS results confirm landmark data from the phase 3 BOREAS study and show Dupixent significantly reduced exacerbations by 34% and improved lung function, compared to placebo, in uncontrolled chronic obstructive pulmonary disease (COPD) with evidence of type 2 inflammation.
Dupixent® (dupilumab) Significantly Reduced COPD …
WEBNov 27, 2023 · NOTUS trial met its primary endpoint with overwhelming efficacy, showing Dupixent significantly reduced exacerbations by 34% compared to placebo in patients with moderate-to-severe COPD with evidence of type 2 inflammation (i.e., blood eosinophils ≥300 cells per μL), confirming results from the landmark BOREAS pivotal trial.
Second positive Phase 3 trial for Dupixent® | Sanofi
WEBNov 27, 2006 · The second Dupixent ® (dupilumab) investigational Phase 3 chronic obstructive pulmonary disease (COPD) trial (NOTUS) has shown that Dupixent significantly reduced (34%) exacerbations, confirming positive published results from the landmark Phase 3 BOREAS trial.
Sanofi and Regeneron Biologic Drug Dupixent Notches a New …
WEB1 day ago · Dupixent, a Sanofi and Regeneron Pharmaceuticals drug, is now approved for chronic obstructive pulmonary disease (COPD), a progressive lung disease prevalent in smokers. It’s the sixth FDA ...